STOCK TITAN

Foghorn Therapeutics Inc. - $FHTX STOCK NEWS

Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: $FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Foghorn Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Foghorn Therapeutics's position in the market.

Rhea-AI Summary
Foghorn® Therapeutics Inc. (Nasdaq: FHTX) to present clinical data from Phase 1 dose escalation study of FHD-286 in AML and MDS at ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
-
Rhea-AI Summary
Foghorn Therapeutics provides financial and corporate update, with a focus on the FHD-286 combination study in AML. The company presented preclinical data for its Selective EP300 and Selective CBP programs. It also announced a cash runway into the first half of 2026 and a collaboration with Loxo@Lilly. Collaboration revenue increased, while research and development expenses decreased.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
-
Rhea-AI Summary
Foghorn Therapeutics will present new data from its preclinical and clinical programs at the 6th Annual Targeted Protein Degradation Summit and the Connective Tissue Oncology Society Annual Meeting. The presentations will cover advancements in degraders targeting key chromatin regulators involved in disease/oncology and preliminary results from a Phase 1 study of FHD-609 in patients with advanced synovial sarcoma or SMARCB1-loss tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences clinical trial
Rhea-AI Summary
Foghorn Therapeutics to present clinical data on FHD-286 at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
-
Rhea-AI Summary
Foghorn Therapeutics announces new clinical and pre-clinical data for its inhibitors FHD-286 and FHD-609 to be presented at AACR-NCI-EORTC International Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences clinical trial
-
Rhea-AI Summary
Stoke Therapeutics appoints Ian Smith to its Board of Directors, bringing significant experience in the development of medicines for rare genetic diseases. Smith's expertise and track record in the biotech industry will be valuable as Stoke advances STK-001 for Dravet syndrome. This represents a unique opportunity to develop disease-modifying medicines for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
Rhea-AI Summary
Foghorn Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary
Foghorn Therapeutics announces dosing of first patient in Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
Foghorn Therapeutics Inc.

Nasdaq:FHTX

FHTX Rankings

FHTX Stock Data

260.08M
21.35M
24.79%
61.83%
2.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About FHTX

foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.